![]() The idea is to find out how genetic variations affect disease in order to create appropriate and even personalized treatments. Meanwhile, the Multiomics Suite is designed to tackle genomic data analysis. "We are partnering with Google on exploring how AlphaFold2 can potentially accelerate our drug discovery process, speeding up our researchers' ability to conduct their experiments on Google Cloud's scalable, accelerator-optimized compute platform," said Pfizer's principal computational scientist, Nicholas Labello. This could effectively speed up drug discovery and lower costs.Įarly adopters for the suite "include multinational pharmaceutical companies like Pfizer and industry-leading biotech companies including Cereval," Google Cloud wrote in a press release. Specifically, it's designed to help scientists identify biological targets that researchers can develop treatments around. The Target and Lead Identification Suite aims to help drug companies better understand proteins and amino acids that are key to drug development. Google's Cloud division is the latest to join that race with two new suites aimed at addressing drug discovery while advancing precision medicine, it announced. It can cost billions of dollars to develop drugs and a large percentage fail at the trial stage, so a number of companies are deploying AI to help in that area.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |